Navigation Links
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Date:11/6/2009

PARIS, November 6 /PRNewswire/ --

- Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid (Zyvox, Pfizer NYSE:PFE).

The comparative Phase II trial with NXL103 is a prospective, multicenter, investigator-blinded, two-arm, parallel group study carried out in adults, either in hospital or as outpatients, with ABSSSI. Patients will be randomized to receive either NXL103 (500 mg twice a day) or linezolid (600mg twice a day), with 120 patients receiving NXL103 and 60 receiving linezolid. The treatment period in both study arms will be between 10 and 14 days.

The primary endpoint of the study is the clinical outcome in the clinically evaluable population at the Test of Cure (TOC) visit (7 days post-therapy). Secondary end points of the study include microbiological response at the TOC visit as well as evaluating the tolerability and safety of NXL103.

This comparative Phase II study is expected to recruit a total of 180 patients from approximately 20 sites in the USA and Central America. The study is expected to be completed in 2010 and is a critical part of Novexel's clinical development plan for NXL103 which is focused on its potential to be used in hospitals and out-patients as an oral agent for the treatment of infections caused by Gram-positive organisms, including MRSA. Currently, physicians have a limited choice of a
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
2. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
5. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and ... of the  "2015 Strategies in the Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... of the orthopedics market, including forecasts for ... categories. , ,In addition, the report presents ...
(Date:5/27/2015)... Research and Markets ( ... the  "North America Mammography Market - Growth, ...  report to their offering.      ... detailed type of imaging that customs a ... mammography exam, called a mammogram, is used ...
(Date:5/27/2015)... 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity Analysis ... suffer from a series of diverse complications arising from ... blood or tissues, which cause a rapidly progressing hyperactive ... rates near 50% depending on disease severity. The syndrome ... of the global marketplace, which for the purposes of ...
Breaking Medicine Technology:Global Orthopedics Market Strategies 2015 2North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
... 2012   CANTEL MEDICAL CORP. (NYSE:CMN) announced today ... presenting at the Needham & Company, LLC  14th Annual ... AM ET on Wednesday, January 11, 2012 at The ... session immediately following the presentation. In addition, Mr. Krakauer ...
... 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... focused on cardiac and vascular surgery, announced today that ... position of Vice President, Research and Development; and David ... President, Market Development Surgical Adhesives and Starch Medical Relations.  ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5
(Date:5/27/2015)... 2015 Hundreds of Risperdal lawsuits ... individuals who allegedly suffered gynecomastia (male breast growth) ... the antipsychotic drug continue to move forward in ... Philadelphia Court of Common Pleas. According to court ... trial program, as the third trial involving Risperdal’s ...
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 In ... are getting tighter, it can be challenging for doctors ... for cutting edge treatments. , Austin-based HealthTronics, ... with minimally invasive, mobile medical therapies for clinically sophisticated ... portfolio with the acquisition of Laser Ventures, Inc ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ... for enterprise organizations, announced today that SanMar Corporation ... its time, attendance and point tracking processes for ... United States. , Family-owned since 1971, Seattle-based ... retail, private label, and mill brands. SanMar supplies ...
(Date:5/27/2015)... Little Rock, AR (PRWEB) May 27, 2015 ... and Medix today announce a partnership to provide ... the Medix community. This collaboration seeks to strengthen ... skills measurement through CMSA’s CKP program. The mutually ... focused on identifying individual skills of talent in ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... Ltd, a Pune-based company have jointly come out with ... this at a press conference here on Thursday,// NCL ... the chirally pure S-Amlodipine, a product of their collaborative ... suffering from hypertension. ,Stating that Emcure is ...
... that has receive only a little scientific interest and virtually ... and respiratory health. A study of over 2,000 children ... issue. The study appeared in the January 15, 2002 ... and potassium intakes were associated with lower lung function. ...
... company has finalized development of a digital screening ... of diagnosing melanomas, the third most common cancer ... said that in terms of its ability to ... analysis and computer-aided diagnostic software for SolarScan, which ...
... France observed in a study that red wine drinkers ... "good" cholesterol. This helps show some light on why ... disease. // ,Researchers compared HDL cholesterol levels between ... who are regular drinkers and those who are heavy ...
... at the University of Michigan, made a new study ... patients after head and neck surgery. Ann Arbor say leeches ... who have surgery// to remove cancer in and around the ... ,Doctors say about 15 percent of patients develop obstructions ...
... recall test is able to differentiate those who will get ... a condition of older people - so we can expect ... ages.// Treatments are now available and they seem to work ... a priority. ,Researchers at the University of Toronto ...
Cached Medicine News:Health News:Latest device for identifying Melanomas 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of group A Streptococcal antigen from throat swabs...
Medicine Products: